Carta al EditorLa herramienta FRAX® en la prevención de fracturas asociadas al tratamiento de privación androgénica en el cáncer de próstataThe FRAX® tool in the prevention of fractures associated with androgenic deprivation therapy for prostate cancer
Bibliografía (10)
- et al.
Efecto del tratamiento del carcinoma de mama y del carcinoma de próstata sobre la masa ósea
Med Clin (Barc)
(2013) - et al.
Precauciones necesarias al utilizar los umbrales predictivos de la herramienta FRAX® en población española para decidir la necesidad de solicitar una densitometría ósea axial
Aten Primaria
(2012) - et al.
Predicción de fracturas por fragilidad o predicción de osteoporosis densitométrica. ¡Esta es la cuestión!
Med Clin (Barc)
(2013) - et al.
Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population
Med Clin (Barc)
(2011) - et al.
Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort
Bone
(2012)
There are more references available in the full text version of this article.
Cited by (4)
Osteoporosis, bone mineral density and CKD–MBD complex (I): Diagnostic considerations
2018, NefrologiaCitation Excerpt :In the general population, active therapeutic intervention is advised in patients with high-risk FRAX® and those whose re-evaluated risk falls above a certain threshold (i.e. >10% for major fractures and/or >3% for hip fracture, according to countries and authors) (Fig. 3). Given that FRAX® appears to underestimate the risk of fracture in the Spanish cohort,45 later studies have re-evaluated its usefulness in our general population,46,47 and densitometry/treatment is now advised in patients with >7.5% 10-year probability of major osteoporotic fracture (Fig. 4). Finally, we believe it is important to point out that an increasing number of studies have recognised the close link between vascular disease and bone pathology.48
Copyright © 2013 Elsevier España, S.L. All rights reserved.